Clinics across the United States are increasingly marketing unproven umbilical cord stem cell infusions to families of autistic children, despite warnings from the FDA that such treatments are often illegal and lack scientific validation. While providers promise improvements in social and behavioral outcomes, federal regulators and independent researchers maintain that no clinical evidence supports these high-cost procedures, which can exceed $20,000 per session.
Why are stem cell clinics targeting autism?
Providers are leveraging parental demand for autism interventions to market “regenerative medicine” services, often justifying their operations through misinterpretations of federal law. According to the FDA, any stem cell treatment offered outside of an approved clinical trial is likely an illegal product. Despite this, companies like the Miami-based Better Stem have begun offering infusions for autism, incorrectly citing the 2018 Right to Try Act. Jeff Cohen, an expert with the Florida Healthcare Law Firm, notes that the Right to Try Act is legally restricted to patients with terminal, life-threatening conditions—a definition that does not include autism.
The most comprehensive clinical trial to date, conducted by Duke University on 180 children, found that umbilical cord stem cell infusions provided no significant therapeutic benefits for the majority of participants.
What is the role of federal leadership?
US Health Secretary Robert F. Kennedy Jr. has publicly signaled support for alternative health providers operating in this space. Kennedy has appeared at summits organized by Autism Health, an advocacy group that promotes stem cell infusions, stating that the issue is “no longer on the fringe.” Furthermore, Kennedy appointed Tracy Slepcevic, an advocate for alternative autism therapies, to the federal Autism Coordinating Committee. This alignment between executive leadership and alternative providers marks a shift in the regulatory environment, even as Kennedy acknowledges the potential for “charlatans” to emerge in a less restricted market.
How do clinics justify these treatments?
Clinics often frame their services as cutting-edge research, even when the methodology lacks regulatory oversight. Ed Clay, founder of the Cellular Performance Institute (CPI) in Tijuana, Mexico, stated that his facility is launching a $2 million clinical trial for 120 children. Clay emphasized that his team includes PhDs from institutions like Harvard and Stanford. However, other providers, such as those presenting at the San Diego Autism Health summit, have proposed protocols involving cells derived from slaughtered sheep and rabbits—a practice that differs sharply from the human umbilical cord infusions offered by US-based clinics.
Are there risks to these procedures?
While some clinical trials have reported minimal safety concerns regarding properly administered human stem cells, the primary risk involves the lack of standardized regulation. The FDA warns that parents seeking these treatments outside of approved trials are vulnerable to deception. Costs are significant; families frequently pay over $10,000 per infusion, often raising the funds through donations. Families like those of four-year-old Ollie from Utah, who is scheduled for an infusion in Florida, report that they are pursuing these options because they feel traditional medical systems offer insufficient support for their children’s needs.
Frequently Asked Questions
- Is stem cell therapy FDA-approved for autism? No. The FDA has not approved any stem cell products for the treatment of autism.
- Does the Right to Try Act cover autism? No. The act is limited to patients with terminal, life-threatening diseases.
- What are the costs associated with these treatments? Procedures can cost between $12,000 and $20,000 per treatment, often excluding travel and follow-up costs.
- Are there scientific studies proving this works? No. The largest placebo-controlled trial, led by Duke University, did not find significant benefits for children with autism.
Have you or a family member encountered predatory medical marketing? Share your experiences in the comments section below to help other families stay informed. Subscribe to our newsletter for ongoing coverage of healthcare policy and medical research.